Patritumab Deruxtecan Shows Promise in Treating Patients with EGFR-Mutated NSCLC

2020 Year in Review: Non–Small-Cell Lung Cancer —February 6, 2021

Categories:

Lung Cancer

A phase 1 clinical trial of the HER3-directed antibody–drug conjugate patritumab deruxtecan shows potential for treating patients with EGFR-mutated NSCLC.

Patients with advanced EGFR-mutated non–small-cell lung cancer (NSCLC) have a poor prognosis when EGFR tyrosine kinase inhibitors (EGFR-TKIs) and platinum-based chemotherapy fail. At the ESMO Virtual Congress 2020, researchers presented safety and efficacy results from a phase 1 clinical trial of the HER3-directed antibody–drug conjugate patritumab deruxtecan in patients with EGFR-mutated NSCLC

Patients with EGFR-mutated NSCLC and previous EGFR-TKI and platinum-based chemotherapy were enrolled in the trial. The primary objective is the assessment of activity by overall response rate as reviewed by a blinded independent central review. The secondary objective is evaluating the safety of patritumab deruxtecan administered intravenously every 3 weeks.

A total of 56 patients were evaluated for a response to 5.6 mg/kg of patritumab deruxtecan. At cutoff, 28 patients remained on treatment, and 6 of those patients had only 1 tumor evaluation. Enrolled patients had a median of 4 (range, 1-9) treatment regimens for metastatic disease. Fifty-one of the patients had received platinum-based chemotherapy prior to trial enrollment. A total of 49 patients had received osimertinib prior to trial enrollment, and the median number of EGFR-TKI treatments was 2 (range, 1-4). Twenty-seven patients had metastases of the central nervous system.

Patients were treated for a median of 3.5 months (range, 1-14 months) with a median follow-up of 5.4 months (range, 0.3-15 months). Decreased platelet counts (25%) and decreased neutrophil counts (16%) were the most common treatment-induced adverse events with a grade ≥3 rating.

Nearly all tumors had HER3 expression. Patients had various EGFR-TKI resistance mechanisms, including EGFR C797S mutation, MET amplification, HER2 mutation, BRAF fusion, and PIK3CA mutation. Patients with these various EGFR-TKI resistance mechanisms showed a response to patritumab deruxtecan treatment.

The authors concluded that patritumab deruxtecan showed promise as a safe and effective treatment in patients with advanced or metastatic EGFR-mutated NSCLC that failed EGFR-TKI or platinum-based treatments.

Reference
Yu HA, et al. ESMO 2020. Abstract LBA62.

Related Articles
Importance of Early Detection in Lung Cancer: Elevating the Navigator’s Role
July 2022 Vol 13, No 7
With a malignancy like lung cancer, early detection can quite literally mean the difference between life and death. Despite this, lung cancer screening and incidental pulmonary nodule (IPN) management are still sorely lacking in the United States, according to Kim Parham, BSN, RN, CB-BN, vice president, Strategic Partnerships and Clinical Liaison, Thynk Health, and Shawn Perkins, BSN, RN, OCN, a thoracic services nurse navigator at Cone Health Cancer Center at Alamance Regional.
2022 Midyear Review: Non–Small-Cell Lung Cancer
Special Issues and Supplements
Anxiety and Depression in Advanced Lung Cancer Patients Affected by Symptoms and Therapy
Web Exclusives
Anxiety and depression in patients with advanced lung cancer are associated with poor outcomes when untreated. Radiotherapy, breathlessness, and fatigue are among top predictors of these debilitating conditions.
Last modified: February 8, 2021

Subscribe to the Journal of Oncology Navigation & Survivorship®

To sign up for our print publication or e-newsletter, please enter your contact information below.

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State

    Please enter your mailing address.

    Address
     
    Address Line 2
    City
     
    State
    Zip Code
    Country